Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

MLA

Markus P. Radsak, et al. “Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS).” Blood, vol. 128, Dec. 2016, p. 5551. EBSCOhost, https://doi.org/10.1182/blood.v128.22.5551.5551.

APA

Markus P. Radsak, Joerg Chromik, Karin Mayer, Ulrich Germing, Katharina Götze, Philipp Kiewe, Eileen Donovan, Thomas Wolff, Xiaosha Zhang, Matthew L. Sherman, Uwe Platzbecker, Kenneth M. Attie, Abderrahmane Laadem, Dawn Wilson, & Aristoteles Giagounidis. (2016). Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS). Blood, 128, 5551. https://doi.org/10.1182/blood.v128.22.5551.5551

Chicago

Markus P. Radsak, Joerg Chromik, Karin Mayer, Ulrich Germing, Katharina Götze, Philipp Kiewe, Eileen Donovan, et al. 2016. “Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS).” Blood 128 (December): 5551. doi:10.1182/blood.v128.22.5551.5551.